The Relationship Between Antihypertensive Drugs and the Risk of Osteoporotic Fracture- A Retrospective Longitudinal Cohort Study

碩士 === 中國醫藥大學 === 藥學系碩士班 === 101 === Background: As populations are aging, cardiovascular disease and osteoporosis are two major prevalent disease in the world. Many studies suggest that the use of anti-hypertensive drugs is associated with bone mineral density and it may protect patients from osteo...

Full description

Bibliographic Details
Main Authors: Pei-Ling Hsieh, 謝佩玲
Other Authors: 陳鴻儀
Format: Others
Language:zh-TW
Published: 2013
Online Access:http://ndltd.ncl.edu.tw/handle/29022276168083848140
Description
Summary:碩士 === 中國醫藥大學 === 藥學系碩士班 === 101 === Background: As populations are aging, cardiovascular disease and osteoporosis are two major prevalent disease in the world. Many studies suggest that the use of anti-hypertensive drugs is associated with bone mineral density and it may protect patients from osteoporotic fractures. Method: We will therefore perform a retrospective cohort study to explore the relationship between anti-hypertensive drugs and osteoporotic fractures. Study began with the date of the anti-hypertensive prescription at the baseline and follow-up continued until 90 days after the last pill was taken, base on the day supply from the last drug dispensing. This study performed from January 1, 2002 to December 31, 2012. Cox Models were constructed to assess the risk of osteoporotic fractures associated with each of the anti-hypertensive class of drug. Result and Discussion: Of the total 1144 patients in the study, 128 (11.1%) patients developed osteoporotic fracture. The mean age of osteoporotic fracture was 78.9 years and that of non-osteoporotic fracture was 75.6 years. There was a significant difference in age between the 2 groups of patients (P < 0.0001). The risk estimate of osteoporotic fracture after adjusted for gender, age and all risk factors for users of calcium channel blockers (HR 0.70 ; 95% CI 0.49 – 1.00)was lower than nonuser. Angiotensin converting enzyme inhibitor users (ACEI) (HR 1.64 ;95% CI 1.00 – 2.66) had highest risk estimates of osteoporotic fracture.